Does Vaxart Inc (VXRT) offer a good opportunity for investors? | news.google.com • |
Vaxart (NASDAQ:VXRT) Shares Cross Above Two Hundred Day Moving Average of $0.85 | news.google.com • |
VXRT (Vaxart Inc) may reap gains as insiders became active recently | news.google.com • |
Checking in on Travere Therapeutics Inc (TVTX) after recent insiders movement | news.google.com • |
VTLE’s latest rating updates from top analysts. | news.google.com • |
Financial Snapshot: Analyzing Vaxart Inc (VXRT)’s Key Ratio Metrics | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-07 | 2024-09 | -0.1 | N/A | N/A | N/A |
2024-08-08 | 2024-06 | 0.03 | -0.09 | -0.12 | -400.00% |
2024-05-13 | 2024-03 | -0.16 | -0.14 | 0.02 | 12.50% |
2024-03-14 | 2023-12 | -0.15 | -0.12 | 0.03 | 20.00% |
2023-11-02 | 2023-09 | -0.18 | -0.11 | 0.07 | 38.89% |
2023-08-03 | 2023-06 | -0.19 | -0.16 | 0.03 | 15.79% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-06 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-06 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2022-12-18 | B. Riley Securities | Upgrade | Neutral | |
2022-09-01 | Cantor Fitzgerald | Upgrade | Overweight | |
2022-05-18 | B. Riley Securities | Upgrade | Neutral | |
2021-11-01 | Cantor Fitzgerald | Upgrade | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-17 | BERG EDWARD B | General Counsel | 270.71K | Stock Award(Grant) |
2024-03-17 | CUMMINGS JAMES F. | Officer | 330.09K | Stock Award(Grant) |
2024-06-10 | FINNEY MICHAEL J | Director | 686.84K | Stock Award(Grant) |
2024-06-10 | HERON ELAINE J | Director | 40.57K | Stock Award(Grant) |
2024-03-17 | LEE PHILLIP E. | Chief Financial Officer | 241.81K | Stock Award(Grant) |
2024-03-17 | LO STEVEN | Chief Executive Officer | 250.00K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Cantor Fitzgerald, L. P. | 7.09M | 5.17M | 4.66% |
2023-06-29 | Vanguard Group Inc | 6.89M | 5.03M | 4.54% |
2023-06-29 | Millennium Management Llc | 2.14M | 1.56M | 1.41% |
2023-06-29 | Blackrock Inc. | 1.93M | 1.41M | 1.27% |
2023-06-29 | Geode Capital Management, LLC | 1.57M | 1.15M | 1.03% |
2023-06-29 | Renaissance Technologies, LLC | 792.01K | 578.16K | 0.52% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 4.07M | 2.97M | 2.68% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.77M | 1.29M | 1.16% |
2023-05-30 | Fidelity Extended Market Index Fund | 631.59K | 770.54K | 0.42% |
2023-05-30 | Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 559.90K | 683.08K | 0.37% |
2023-05-30 | Vanguard Health Care Index Fund | 480.63K | 586.37K | 0.32% |
2023-06-29 | Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 361.97K | 264.24K | 0.24% |
Dividend | Date |
---|---|
0.1847 | 2012-11-09 |
Split | Date |
---|---|
1 : 11 | 2018-02-14 |
0.16667 : 1 | 2012-11-09 |
-
Just new to this stock bought 2k at 7.55 hopefully
-
Soon articles like this will have to mention Vaxart by name:
-
-
$VXRT fellow who are saying they regret they didn’t buy at 7.50.. i say dont regret you will get chances to load at 3 doller also very soon. Lol
-
$VXRT if you didn’t sell at $20 and now not buying this awesome dip just stop trading...lol
-
I did not sell on Feb 2nd, but I learned my lesson on the hard way, “too good to be true, take at least 50% “. We are the best stop loss
-
-
Vaxart: Stock Drop Following Phase 1 Data For Oral COVID-19 Vaccine Is A Buying Opportunity https://seekingalpha.com/article/4403369-vaxart-stock-drop-following-phase-1-data-for-oral-covidminus-19-vaccine-is-buying-opportunity
-
It’s all same old crap of scaring away the little guy. I continue adding up at these rates. Sky is the limit.
-
ALYI Welcomes Elon Musk And Tesla To Texas – Now How About Joining Us In Africa Too?
December 11, 2020 Stock Day Media 592 Views ALYI, elonmusk, Elonmusknews, tesla
PR NewswireDALLAS, Dec. 11, 2020
DALLAS, Dec. 11, 2020 /PRNewswire/ — Alternet Systems, Inc. (USOTC: ALYI), an electric vehicle innovation company headquartered in Dallas, Texas, today welcomed Elon Musk and Tesla to Texas.
-
Not only that the lake of neutralising antibodies (specific to the corona virus) were not found on the participants who took a single doses only of the vaccine, but also have to be said that, however, they was found in nasal swab samples of the participants who received two doses...
What is the different between this vaccine and those of Pfizer and moderna??? They also need to use two doses...
However, our uniq advantages - no need for needles and the logistic one (room temperature) - still exist.How can someone say this results are disappointing?
We are attacked by tutes.
Keep your diamonds
-
-
Let’s post on Twitter & soc media, lets make trending topic on VXRT
https://finance.yahoo.com/news/vaxart-tanks-58-oral-covid-081354958.html
-
I told my group that "Understanding the risks of buying a company with only Phase 1 data that has not been fully evaluated by the scientific and medical communities, we could start new positions between $9 and $11."
Their data may not impress scientists right now, but I'm betting they will still get funding to proceed with the next phases. And the potential is intriguing for at least two reasons besides the possibility of a COVID pill.
First, if successful, they will be targeting a unique opportunity as the only "mucosal" vaccine after Merck recently abandoned their attempts. According to some doctors, novel coronavirus is a pathogen of a mucosal organ, different than those viruses that attack systemic organs. Current vaccines are systemic, and can only reduce disease severity.
Secondly, if successful, a pill for COVID could be room-temperature stable and not require extensive cold-chain technologies.
Why own more than one vaccine stock? Because the demand outstrips supply right now, plus countries want differentiated platforms and technology.
-
I told my group that "Understanding the risks of buying a company with only Phase 1 data that has not been fully evaluated by the scientific and medical communities, we could start new positions between $9 and $11."
Their data may not impress scientists right now, but I'm betting they will still get funding to proceed with the next phases. And the potential is intriguing for at least two reasons besides the possibility of a COVID pill.
First, if successful, they will be targeting a unique opportunity as the only "mucosal" vaccine after Merck recently abandoned their attempts. According to some doctors, novel coronavirus is a pathogen of a mucosal organ, different than those viruses that attack systemic organs. Current vaccines are systemic, and can only reduce disease severity.
Secondly, if successful, a pill for COVID could be room-temperature stable and not require extensive cold-chain technologies.
Why own more than one vaccine stock? Because the demand outstrips supply right now, plus countries want differentiated platforms and technology.
-
-
-
Bad PR IgA is a neutralizing antibody, that is in the mucosa.
-
“Vaxart nonetheless be remains confident that its tablet will not only be able to treat the coronavirus but also handle the emerging new strains of the virus”
“Our Phase I results highlight the importance of our differentiated vaccine design, as they suggest VXA-CoV2-1 could have broad activity against existing and future coronavirus strains," Chief Executive Andrei Floroiu said in a statement.
-
Does Vaxart Inc (VXRT) offer a good opportunity for investors?
news.google.com • -
VXRT (Vaxart Inc) may reap gains as insiders became active recently
news.google.com • -
VTLE’s latest rating updates from top analysts.
news.google.com • -
Financial Snapshot: Analyzing Vaxart Inc (VXRT)’s Key Ratio Metrics
news.google.com • -
Is Vaxart Inc (VXRT) a good investment opportunity?
news.google.com • -
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript
seekingalpha.com • -
Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding
seekingalpha.com • -
Vaxart Provides Business Update
globenewswire.com • -
Vaxart Announces $40 Million Underwritten Offering of Common Stock
globenewswire.com • -
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript
seekingalpha.com • -
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
globenewswire.com • -
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
globenewswire.com • -
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript
seekingalpha.com • -
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
globenewswire.com •